Christopher Bowden
Fortune : - $ au 31/07/2026
Fortune : - $ au 31/07/2026
Christopher J.
Bowden is Director at Cedilla Therapeutics, Inc. since 2021 and Independent Director at Bicara Therapeutics, Inc. since 2024.
Former roles include Executive Director-Europe, Middle East & Africa at Bristol Myers Squibb Co. from 2003 to 2006; Independent Director at Alaunos Therapeutics, Inc. from 2019 to 2023; Independent Director at Viridian Therapeutics, Inc. from 2017 to 2020; VP-Product Development Oncology at Genentech, Inc. from 2006 to 2014; Chief Medical Officer at Agios Pharmaceuticals, Inc. from 2014 to 2021; Member of Roche Group from 2006 to 2014; and Chief Medical Officer at Remix Therapeutics, Inc. from 2023 to 2025.
Education includes undergraduate studies at Lake Forest College and a doctorate from Drexel University College of Medicine conferred in 1988.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/06/2026 | 0 ( -.--% ) | - $ | 31/07/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| BICARA THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/08/2024 |
Cedilla Therapeutics, Inc.
Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Engages in discovering and exploiting unique insights into protein stability | Directeur/Membre du Conseil | 21/04/2021 |
| Sociétés | Poste | Fin |
|---|---|---|
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Directeur Technique/Scientifique/R&D | 31/12/2025 |
| ALAUNOS THERAPEUTICS, INC. | Directeur/Membre du Conseil | 30/03/2023 |
| AGIOS PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 01/09/2021 |
| VIRIDIAN THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/10/2020 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/05/2014 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 11 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops therapeutics | Health Technology |
Roche Group
Roche Group Real Estate DevelopmentFinance Manages real estate properties | Finance |
Lake Forest College
Lake Forest College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. BiotechnologyHealth Technology Develops a portfolio of immuno-oncology therapies | Health Technology |
Drexel University College of Medicine
Drexel University College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops and manufactures monoclonal antibody products | Health Technology |
Cedilla Therapeutics, Inc.
Cedilla Therapeutics, Inc. BiotechnologyHealth Technology Engages in discovering and exploiting unique insights into protein stability | Health Technology |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Remix Therapeutics, Inc.
Remix Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company develops molecule therapies to modulate RNA processing and address the underlying drivers of diseases | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national